Inhaled glucocorticoids are the recommended therapy for persistent asthma in children. In prepubertal children, however, the use of inhaled glucocorticoids has been shown to reduce growth velocity, resulting in a linear growth reduction of 0.5 to 3.0 cm (approximately 1 cm on average) during the first few years of therapy. This reduction has been reported for low-to-medium doses, but the degree of reduction is dependent on the type of inhaled glucocorticoid and the delivery method.
訂正箇所→「配送方法」を「吸入方法」に変えてください。